Re: IDIX’s newest director
Ms. Howson fills the open seat on the BoD that IDIX has had since Jan 2010 (when Pamela Thomas-Graham left to take a position at Credit Suisse). With Howson’s appointment, independent directors now comprise a majority (5 of 9 seats) on IDIX’s BoD.
If what IDIX wanted was a director with experience in biotech partnerships and M&A transactions, a better pick than Ms. Howson would be hard to find. She has held senior business-development positions at BMY, LEXG, and SmithKline Beecham (now part of GSK). Howson also has an engineering degree from Technion in Israel, one of the world’s premiere academic institutions.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
